Wave Plummets 50% on Obesity Data

Investors zeroed in on the mere 0.9% dip in body weight and 3.3% decline in waist circumference (both placebo-adjusted) reported in the 32-participant 240 mg dose cohort following a six-month follow-up review during the Phase I INLIGHT trial (NCT06842186), designed to assess WVE-007 in healthy individuals living with overweight or obesity conditions.

The post Wave Plummets 50% on Obesity Data appeared first on GEN - Genetic Engineering and Biotechnology News.